Dr. Nancy J. Cox, an influenza expert at the Centers for Disease Control and Prevention in Atlanta, which is helping prepare a seed virus, said there was no guarantee on that time frame.
Of the 47 different adenovirus species, only a few commonly cause illness in humans; it is thus possible to prepare a vaccine against these viruses.
Microarrays were hybridized with amplicons prepared from cDNA of Influenza A virus.
Plaque-purified virus was used to prepare a large-scale stock of the CVB4/p24 733) recombinant in LLC-MK2(D) cells.
After 10 serial chicken lung passages of the QA23 virus, we prepared a stock of the virus by inoculating the 10th passaged chicken lung homogenate into embryonated chicken eggs; the virus was designated QA23CkA10 (Table 2).
We prepared a Modified Vaccinia virus Ankara (MVA) vector encoding nucleoprotein and matrix protein 1 (MVandP+M1) and conducted a phase I clinical trial in healthy adults.
Because preparing a vaccine against such a virus could take 6 months, antiviral drugs would be the first line of defense against pandemic flu.
She said scientists at the C.D.C. were preparing a "seed stock" from virus samples that could be used for a vaccine.
To prepare virus stocks, cells permissive for the virus to be amplified (Vero-Slam, Vero, HepG2 (ATCC HB-8065), and Madin-Darby canine kidney (MDCK)) were infected and incubated at 37°C.
